Long-Term Outcomes after Surgical Resection for Synchronous or Metachronous Hepatic and Pulmonary Colorectal Cancer Metastases.


Journal

Digestion
ISSN: 1421-9867
Titre abrégé: Digestion
Pays: Switzerland
ID NLM: 0150472

Informations de publication

Date de publication:
2020
Historique:
received: 06 07 2018
accepted: 25 01 2019
pubmed: 21 2 2019
medline: 1 12 2020
entrez: 21 2 2019
Statut: ppublish

Résumé

At present, benefits of surgical resection and appropriate selection criteria in patients affected by both hepatic and pulmonary metastases of colorectal cancer (CRC) are under discussion. Our analysis focused on a surgical series of such patients and our final aim consisted in identifying potential prognostic factors. Eighty-five patients undergoing resection of both hepatic and pulmonary metastases at 2 Healthcare Institutions from January 1993 to June 2015 were retrospectively reviewed as concerned clinical information, surgical notes and pathological features. Patient, treatment, and outcome variables were analyzed by use of log-rank tests, Cox regression, and Kaplan-Meier methods. Liver turned out as the first site of metastasis in 75% patients, lung in 13% patients, and both sites in 12% patients. Multiple hepatic metastases were detected in 67% patients and pulmonary metastases in 31% patients. Two hundred eighteen surgical interventions were performed (mean 2.56 for each patient). Overall survival (OS) rates at 3-, 5-, and 10-year follow-up from colorectal resection were 94, 79, and 38% respectively. Median OS was 8.31 years. Survival turned out significantly longer for patients with disease-free interval (DFI) exceeding 1 year between first metastasectomy and diagnosis of second metastases and in patients affected by metachronous pulmonary metastases. Surgical resection of both hepatic and pulmonary metastases of CRC represents a safe and effective treatment. It might lead to rewarding long-term survival rates in high selected patients. Shorter DFIs between first metastasectomy and diagnosis of second metastases can determine worse prognoses. In addition, poor outcomes could be predicted also for patients affected by synchronously detected pulmonary CRC metastases, although further confirmatory analyses are strongly required.

Sections du résumé

BACKGROUND/AIMS OBJECTIVE
At present, benefits of surgical resection and appropriate selection criteria in patients affected by both hepatic and pulmonary metastases of colorectal cancer (CRC) are under discussion. Our analysis focused on a surgical series of such patients and our final aim consisted in identifying potential prognostic factors.
METHODS METHODS
Eighty-five patients undergoing resection of both hepatic and pulmonary metastases at 2 Healthcare Institutions from January 1993 to June 2015 were retrospectively reviewed as concerned clinical information, surgical notes and pathological features. Patient, treatment, and outcome variables were analyzed by use of log-rank tests, Cox regression, and Kaplan-Meier methods.
RESULTS RESULTS
Liver turned out as the first site of metastasis in 75% patients, lung in 13% patients, and both sites in 12% patients. Multiple hepatic metastases were detected in 67% patients and pulmonary metastases in 31% patients. Two hundred eighteen surgical interventions were performed (mean 2.56 for each patient). Overall survival (OS) rates at 3-, 5-, and 10-year follow-up from colorectal resection were 94, 79, and 38% respectively. Median OS was 8.31 years. Survival turned out significantly longer for patients with disease-free interval (DFI) exceeding 1 year between first metastasectomy and diagnosis of second metastases and in patients affected by metachronous pulmonary metastases.
CONCLUSIONS CONCLUSIONS
Surgical resection of both hepatic and pulmonary metastases of CRC represents a safe and effective treatment. It might lead to rewarding long-term survival rates in high selected patients. Shorter DFIs between first metastasectomy and diagnosis of second metastases can determine worse prognoses. In addition, poor outcomes could be predicted also for patients affected by synchronously detected pulmonary CRC metastases, although further confirmatory analyses are strongly required.

Identifiants

pubmed: 30783050
pii: 000497223
doi: 10.1159/000497223
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

144-155

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Maurizio Zizzo (M)

Surgical Oncology Unit, Azienda Unità Sanitaria Locale/IRCCS of Reggio Emilia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, zizzomaurizio@gmail.com.
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy, zizzomaurizio@gmail.com.

Carla Galeone (C)

Thoracic Surgery Unit, Azienda Unità Sanitaria Locale/IRCCS of Reggio Emilia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

Luca Braglia (L)

Infrastructure Research and Statistics, Azienda Unità Sanitaria Locale/IRCCS of Reggio Emilia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

Lara Ugoletti (L)

Surgical Oncology Unit, Azienda Unità Sanitaria Locale/IRCCS of Reggio Emilia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

Alessandra Siciliani (A)

Thoracic Surgery Unit, Università Cattolica del Sacro Cuore-Policlinico "A. Gemelli", Roma, Italy.

Dania Nachira (D)

Thoracic Surgery Unit, Università Cattolica del Sacro Cuore-Policlinico "A. Gemelli", Roma, Italy.

Stefano Margaritora (S)

Thoracic Surgery Unit, Università Cattolica del Sacro Cuore-Policlinico "A. Gemelli", Roma, Italy.

Claudio Pedrazzoli (C)

Surgical Oncology Unit, Azienda Unità Sanitaria Locale/IRCCS of Reggio Emilia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

Massimiliano Paci (M)

Thoracic Surgery Unit, Azienda Unità Sanitaria Locale/IRCCS of Reggio Emilia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

Filippo Lococo (F)

Thoracic Surgery Unit, Azienda Unità Sanitaria Locale/IRCCS of Reggio Emilia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH